Charles River Laboratories International, Inc. (CRL)
$
170.64
+3.61 (2.12%)
Key metrics
Financial statements
Free cash flow per share
11.7702
Market cap
8.5 Billion
Price to sales ratio
2.1029
Debt to equity
0.8308
Current ratio
1.3604
Income quality
-12.1369
Average inventory
284.9 Million
ROE
-0.0201
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Charles River Laboratories International, Inc. is a prominent non-clinical contract research organization that offers a range of services, including drug discovery, non-clinical development, and safety testing across various global markets, including the United States, Europe, Canada, and the Asia Pacific. The cost of revenue for the company is $2,718,168,000.00 showcasing its production and operational expenses that support its comprehensive service offerings. With an operating income ratio of 0.06 the company's operational profitability margin reflects its ability to maintain efficiency in its business activities. Additionally, the company incurred an interest expense of $126,288,000.00 which indicates its debt servicing obligations and financial commitments. The total costs and expenses for the company amount to $3,822,642,000.00 reflecting its overall spending in pursuit of excellence in research services. Furthermore, the gross profit ratio is 0.33 which assesses the efficiency of the company's production and sales operations, underscoring its strategic management practices and financial health. Moving forward, the stock is reasonably priced at $155.39 appealing to a broad range of investors seeking opportunities in the market. The stock has an average trading volume of 930,325.00 indicating moderate liquidity, which is favorable for both institutional and retail investors. With a mid-range market capitalization of $8,397,907,334.00 the company is recognized as a steady performer within the competitive landscape. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape through its innovative approaches and extensive portfolio of services. Moreover, it belongs to the Healthcare sector, driving innovation and growth that enhance its reputation and stability in the industry as it responds to evolving market needs.
Is Charles River Laboratories International, Inc. (CRL) a good investment?
Investing in Charles River Laboratories International, Inc. (CRL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Charles River Laboratories International, Inc. (CRL)'s stock forecast?
Analysts predict Charles River Laboratories International, Inc. stock to fluctuate between $91.86 (low) and $230.02 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Charles River Laboratories International, Inc.'s market capitalization?
As of 2025-10-13, Charles River Laboratories International, Inc.'s market cap is $8,397,907,334, based on 49,214,178 outstanding shares.
How does Charles River Laboratories International, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Charles River Laboratories International, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Charles River Laboratories International, Inc. (CRL) stock?
To buy Charles River Laboratories International, Inc. (CRL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CRL. Place an order (Market, Limit, etc.).
What is the best time to invest in Charles River Laboratories International, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Charles River Laboratories International, Inc. perform in the last earnings report?
Revenue: $4,049,989,000 | EPS: $0.20 | Growth: 0%.
Where can I find Charles River Laboratories International, Inc.'s investor relations reports?
Visit https://www.criver.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Charles River Laboratories International, Inc.?
You can explore historical data from here
What is the all-time high and low for Charles River Laboratories International, Inc. stock?
All-time high: $460.21 (2021-09-24) | All-time low: $91.86 (2025-04-11).
What are the key trends affecting Charles River Laboratories International, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Here are three resilient medical services stocks, Labcorp, Charles River Laboratories and Teladoc, that are poised to outperform amid staffing shortages and digital healthcare growth.
benzinga.com
Charles River Laboratories International Inc. (NYSE:CRL) is entering a critical point in its 18-phase Adhishthana cycle. The stock currently sits in Phase 17 on the weekly chart, with Phase 18, its final phase, set to begin on October 20.
businesswire.com
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Chief Financial Officer Transition.
zacks.com
Charles River shares rise after new collaborations with PICI and CHLA, boosting its oncology and cell therapy pipeline momentum.
seekingalpha.com
Charles River Laboratories International, Inc. (NYSE:CRL ) Baird 2025 Global Healthcare Conference September 10, 2025 9:40 AM EDT Company Participants James Foster - Chairman, President & CEO Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Presentation Eric Coldwell Senior Research Analyst Good morning, everyone.
seekingalpha.com
Charles River Laboratories International, Inc. (NYSE:CRL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants James Foster - Chairman, President & CEO Conference Call Participants Kallum Titchmarsh - Morgan Stanley, Research Division Presentation Kallum Titchmarsh Equity Analyst Okay. Great. I think we can get started.
zacks.com
Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.
zacks.com
CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.
seekingalpha.com
Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.
seekingalpha.com
Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable. Ongoing risks include regulatory pressure to phase out animal testing and weak organic revenue growth, especially in the Discovery and Safety Assessment segment. Management raised full-year guidance, but H2 faces margin and revenue headwinds; Q3 EPS is expected to decline sequentially.
See all news
